



## **Welcome to an Elekta R&D update at University Medical Center Utrecht**

STOCKHOLM, December 22, 2014 – Elekta welcomes investors, analysts and media to an update on its investments in R&D, with special attention to the Atlantic project: a magnetic resonance imaging (MRI) guided radiation therapy system.

This event will be held on Thursday, January 22, 2015, from 10:30 – 12:30 CET at University Medical Center (UMC) Utrecht in the Netherlands.

Jan Lagendijk, Professor and Head of Radiation Oncology, Radiology and Nuclear Medicine Physics at UMC and Marco van Vulpen, Professor of Radiation Therapy and MRI, also at UMC, will discuss the clinical relevance of MRI-guided radiation therapy and show the world's first fully integrated research system, as it nears completion at UMC.

Niklas Savander, Elekta's President and CEO; Dee Mathieson, Senior Vice President, Elekta Oncology; and Kevin Brown, Elekta's Global Vice President Scientific Research, will talk about Elekta's R&D investments in general as well as the status of the project and the milestones to market introduction of the MRI-guided linear accelerator in particular.

Investors, analysts and media who would like to attend, are kindly requested to give notice by e-mail to [elisabeth.natt.och.dag@elekta.com](mailto:elisabeth.natt.och.dag@elekta.com) before January 15.

It will also be possible to listen to the presentations over the phone and via the web. Links and phone numbers will be published in January 2015.

###

### **For further information, please contact:**

Gert van Santen, Group Vice President Corporate Communications, Elekta AB

Tel: +31 653 561 242, e-mail: [gert.vansanten@elekta.com](mailto:gert.vansanten@elekta.com)

Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB

Tel: +46 722 215 017, e-mail: [tobias.bulow@elekta.com](mailto:tobias.bulow@elekta.com)

Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 15:30 CET on December 22, 2014.

### **About Elekta**

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals



worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: [www.elekta.com](http://www.elekta.com).